Jubilant Life Sciences said it received an Establishment Inspection Report (EIR) with Voluntary Action Indicated (VAI) status from the USFDA for its solid dosage facility at Salisbury, Maryland, USA.
Jubilant Pharma, a material wholly owned subsidiary of Jubilant Life Sciences, has received the Establishment Inspection Report (EIR) with Voluntary Action Indicated (VAI) status from the United States Food & Drug Administration (USFDA) for its solid dosage facility at Salisbury, Maryland, USA in respect of the inspection conducted by the US-based drug regulator from 24 February 2020 to 28 February 2020.
With the receipt of the EIR, the inspection stands successfully closed. The disclosure was released after trading hours yesterday, 31 March 2020.
Jubilant Life Sciences is an integrated global pharmaceutical and life sciences company engaged in pharmaceuticals, life science ingredients and other businesses including drug discovery solutions.
Shares of Jubilant Life Sciences was locked in 10% upper-circuit at Rs 273.70 on BSE. The stock traded in the range of Rs 252.05 to Rs 273.70 so far.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app